Upifitamab rilsodotin is under clinical development by Mersana Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Upifitamab rilsodotin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Upifitamab rilsodotin overview

Upifitamab rilsodotin is under development for the treatment of ovarian cancer, solid tumors including non-small cell lung cancer, high-grade serous epithelial ovarian, papillary renal cell carcinoma, endometrial cancer, salivary duct carcinoma, papillary thyroid carcinoma and platinum-sensitive ovarian cancer. The drug candidate is an anti-NaPi2b immunoconjugate comprises auristatin molecules conjugated to a humanized anti-NaPi2b monoclonal antibody XMT-1535. It is administered through intravenous infusion. The drug candidate is developed based on dolaflexin antibody drug conjugate technology.

The drug candidate was under development for the treatment of fallopian tube cancer, peritoneal cancer.

Mersana Therapeutics overview

Mersana Therapeutics (Mersana) is a pharmaceutical company. It develops antibody-drug conjugates (ADC) for the treatment of cancer. The company’s pipeline products XMT-1660, XMT-2056, XMT-2068, and XMT-2175 an ADC that targets sodium-dependent phosphate transport protein NaPi2b utilizing the Dolaflexin platform. Mersana utilizes various technologies including DolaLock Technology, Dolaflexin, Dolasynthen, and Immunosynthen in developing ADCs. Its products also include ASN004 which is in the dose escalation stage. The company develops immunoconjugates to deliver payloads of anti-tumor agents directly to cancerous cells. Its products are used to treat multiple cancer indications including gastric cancer and metastatic breast cancer. Mersana is headquartered in Cambridge, Massachusetts, the US.

For a complete picture of Upifitamab rilsodotin’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.